|
|
|
|
 |
|
您現(xiàn)在的位置：產(chǎn)品中心 >>
分子生化試劑 >> 生化試劑 |
Neratinib, Free Base
|
產(chǎn)品編號(hào)： |
N-6404-10 mg
查看說(shuō)明書(shū) |
|
產(chǎn)品名稱(chēng)：
|
Neratinib, Free Base .0 訂購(gòu)此產(chǎn)品 |
|
供應(yīng)商：
|
LC |
|
規(guī)格： |
10 mg |
|
目錄價(jià)： |
5908 |
|
庫(kù)存狀態(tài)： |
|
|
CAS編號(hào)：
|
[698387-09-6] |
|
應(yīng)用范圍： |
|
|
種屬來(lái)源： |
|
|
相關(guān)信息： |
|
|
N-6404 Neratinib, Free Base, >99%Synonyms: [HKI-272]M.W. 557.04 C30H29ClN6O3 [698387-09-6]
Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO at 2 mg/mL with warming; very poorly soluble in ethanol; very poorly soluble in water; maximum solubility in plain water is estimated to be about 5-20 µM; buffers, serum, or other additives may increase or decrease the aqueous solubility. Disposal: A
•Neratinib, also known as HKI-272, is considered to be a second-generation inhibitor of the ErbB family of receptor kinases. Sequist, L.V., et al. "Second-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer." Oncologist 12: 325-330 (2007).
•Neratinib is an irreversible inhibitor of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER-2) tyrosine kinases by targeting a cysteine residue in the ATP-binding site of the receptor. Rabindran, S.K., et al. "Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase." Cancer Res. 64: 3958-3965 (2004).
•Neratinib inhibits the proliferation of HER-2 overexpressing human breast cancer cell lines and EGFR-dependent cells in vitro. In vivo, neratinib is active against HER-2- and EGFR-dependent tumor xenograft models. Rabindran, S.K., et al. "Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase." Cancer Res. 64: 3958-3965 (2004).
•Acquired resistance of non-small cell lung cancers to gefitinib because of a T790M mutation in the EGFR kinase domain is circumvented by neratinib. Kwak, E.L., et al. "Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib." Proc. Natl. Acad. Sci. USA 102: 7665-7670 (2005).
•Neratinib is active against HER-2-positive breast cancer in patients. Wong, K.K., et al. "HKI-272, an irreversible pan erbB receptor tyrosine kinase inhibitor: Preliminary phase 1 results in patients with solid tumors." J. Clin. Oncol. 24: 3018 (2006).
•Another CAS number previously assigned to neratinib, namely 736156-77-7, has been deleted by CAS and is no longer in use.
•Sold for laboratory or manufacturing purposes only; not for human, veterinary, food, or household use.
•This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.
•Not available in some countries; not available to some institutions; not available for some uses.
|
|
保存條件： |
|
|
說(shuō)明書(shū)地址： |
點(diǎn)擊查看詳細(xì) |
|
|
|
|
打印此頁(yè) 關(guān)閉此頁(yè) |
上一個(gè)：現(xiàn)貨|雷帕霉素|Rapamycin|西羅莫司|Sirolimus|AY 22989|FRAP[R5000/10MG]
下一個(gè)：Ascomycin[A-1040-1 g/1 g]
|
|
|
 |
|